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Abstract
Single intradermal or intramuscular inoculations of GM-CSF DNAwith the DNA prime for a simian–human immunodeficiency virus (SHIV)-
89.6 vaccine, which consists of DNA priming followed by modified vaccinia Ankara (MVA) boosting, increased protection of both the blood and
intestines against the acute phase of an intrarectal SHIV-89.6P challenge. GM-CSF appeared to contribute to protection by enhancing two antibody
responses: the avidity maturation of anti-Env IgG in blood (p=b0.01) and the presence of long lasting anti-viral IgA in rectal secretions (pb0.01).
The avidity of anti-Env IgG showed strong correlations with protection both pre and post challenge. Animals with the highest avidity anti-Env Ab had
1000-fold reductions in peak viremia over those with the lowest avidity anti-Env Ab. The enhanced IgA response was associated with the best
protection, but did not achieve significance.
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doi:10.1016/j.virol.2007.07.017wide by 2030 (Mathers and Loncar, 2006). Antiretroviral drugs,
although effective for most patients, are available to only a
fraction of infected humans, require treatment for life and have
side effects. The solution to the pandemic is a vaccine capable of
both preventing disease and limiting transmission. The current
pandemic is spread primarily by intravenous drug use and sexual
intercourse, with heterosexual intercourse being the dominant
method for transmission worldwide (UNAIDS and WHO,
2006). Therefore, an effective vaccine will need to protect the
mucosal surfaces of the vagina and rectum as well as blood
against viral transmission.
154 L. Lai et al. / Virology 369 (2007) 153–167Here we report the ability of GM-CSF DNA, delivered with
the DNA prime of a vaccine that consists of DNA priming and
modified vaccinia Ankara (MVA) boosting (DNA/MVA vac-
cine) to enhance protection of the blood as well as the intestines
against the acute phase of a SHIV-89.6P infection. GM-CSFwas
tested for adjuvant activity because of its demonstrated ability to
enhance the protective efficacy of cancer vaccines (Borrello and
Pardoll, 2002; Dranoff et al., 1993) and its early success as an
adjuvant for DNA vaccines in mouse models (Barouch et al.,
2002; Lee et al., 1998; Xiang and Ertl, 1995). GM-CSF is a
critical factor in the development and differentiation of dendritic
cells and monocytes (Inaba et al., 1992). Both of these cell types
are “professional antigen presenting cells” capable of initiating
immune responses by presenting antigens to the immune system
(Banchereau and Steinman, 1998).
The study was done using SHIV-89.6 sequences for immu-
nization (Reimann et al., 1996b) and its highly pathogenic
neutralization-escape variant, SHIV-89.6P, for challenge (Karls-
son et al., 1997; Reimann et al., 1996a). Both the DNA andMVA
immunogens expressed SHIV-89.6 virus-like-particles (VLPs).
These particles contained SIV structural (Gag) and enzymatic
proteins (protease and reverse transcriptase) surrounded by a
viral membrane displaying a native form of the 89.6 HIV-1
envelope glycoprotein (Env). Tests for protection focused on
peak viremia, because peak titers of virus show greater
differences than set point levels of virus (many of which are
below the level of detection) for SHIV-89.6P challenges in our
DNA/MVA vaccinated macaques (Amara et al., 2001). In SIV/
macaque models early viral replication is a critical determinant
of the virulence of an infection (Lifson et al., 1997) and peak
viremia shows a better correlation than set point viremia with
progression to disease within 1 year (p=0.03) (Smith et al.,
1999). Thus, for SHIV-89.6P infections that kill the vast
majority of animals within 1 year, peak viremia is a relevant
correlate for protection.
In a prior study in the SHIV-89.6/SHIV-89.6P model, the use
of GM-CSF as an adjuvant reduced peak viremia by 4-fold and
increased the stringency of control during the chronic phase of
infection as evidenced by reduced frequencies for brief
appearances of re-emergent virus (pb0.01) (Robinson et al.,
2006). In this study, GM-CSF appeared to have enhanced the
elicitation of neutralizing Ab for SHIV-89.6P by enhancing the
avidity maturation of anti-Env Ab. The current study was
undertaken to further study the effects of GM-CSF on the avidity
maturation of anti-Env Ab and the contribution of the avidity of
anti-Env IgG to protection. At the time of challenge, assays were
extended to include tests for mucosal immune responses and
protection of mucosal CD4 T cells.
Our results reveal a single inoculation of GM-CSF DNA
consistently enhancing the avidity maturation of the anti-Env Ab
response. They also reveal a strong direct correlation between
the avidity of anti-Env IgG and protection against peak viremia
(pb0.01). Interestingly, the mucosal studies revealed GM-CSF
also supporting the elicitation of long lasting anti-viral IgA in
rectal secretions (pb0.01). Anti-viral IgA was present in the
secretions of animals with the lowest peak viremias, but did not
show a significant correlation with protection.Results
Immunogens and trial design
The ability of GM-CSF DNA to serve as an adjuvant for the
DNA prime of a DNA/MVA vaccine was tested both by co-
inoculating a dedicated GM-CSF-expressing plasmid with a
VLP expressing SHIV-89.6 vaccine DNA (GM-CSF DNA in
trans) and by expressing GM-CSF DNA in the vaccine DNA in
the place of nef (GM-CSF DNA in cis) (Fig. 1A). In transient
transfections, the dedicated GM-CSF expression vector ex-
pressed 15-times higher levels of GM-CSF than the GM-CSF
expressed in cis (Fig. 1A). However, the cis expression achieved
levels found to be effective in GM-CSF-adjuvanted cancer
vaccines (∼1 μg per 106 expressing cells) (Borrello and Pardoll,
2002) and was directly targeted to cells expressing the vaccine
antigen.
A single immunization with the DNAvaccine in the presence
or absence of GM-CSFDNAwas followed by threeMVA boosts
(Fig. 1B). For animals receiving GM-CSF DNA in trans, a
mixture of equal amounts of DNA/89.6.VLP and DNA/GM-
CSF (1.5 mg of each) were delivered intradermally (i.d.) to
achieve at least some co-localization of cells expressing the
vaccine and adjuvant. Inoculations of GM-CSFDNA in cis were
conducted both i.d. and intramuscularly (i.m.) by inoculating
3 mg of the GM-CSF-expressing vaccine DNA (DNA/89.6.
VLP.GM-CSF). Three boosts with 108 pfu ofMVA/89.6 (Amara
et al., 2001) were delivered by the same route used for the prime
at weeks 8, 24 and 40 (Fig. 1B). Challenges were conducted
intra-rectally with SHIV-89.6P at 32 weeks post the last MVA
inoculation in animals receiving no GM-CSF DNA or inocula-
tions of the GM-CSF DNA in trans, and at 60 weeks post the last
MVA immunization in animals given the GM-CSF DNA in cis
(Fig. 1B). Unvaccinated control animals were included with
both challenges.
Groups receivingGM-CSFDNA in both cis and trans showed
10-fold lower levels of peak viremia than the unadjuvanted
vaccine group following the SHIV-89.6P challenge (Fig. 1C).
No differences were found in the extent of viral control in groups
that had received GM-CSF in cis or in trans (Fig. 1C). Therefore,
to gain statistical power, immune response data for all of theGM-
CSF-adjuvanted animals are considered together.
Protection
The GM-CSF-adjuvanted group had better control of peak
viremia and a more rapid reduction of viremia to the background
for detection than the non-adjuvanted group (Fig. 2A). At peak
viremia, the adjuvanted group had reduced viremia by 10-fold
over that in the non-adjuvanted group (p=0.01), a reduction that
was 30-fold over that in the unvaccinated controls (pb0.001)
(Fig. 2E). By 5 weeks post challenge, 6 out of the 16 GM-CSF-
adjuvanted animals had viral loads below 100 copies per ml of
plasma, whereas none of the non-adjuvanted animals had
achieved this level of control. By 12 weeks post challenge, the
geometric mean viremia for the adjuvanted animals was at our
level of detection (100 copies per ml) and the mean for non-
Fig. 1. Immunogens, immunization schedules, and the elicitation of similar protection in groups receiving GM-CSF DNA in cis and trans. (A) Expression cassettes for
the DNA prime. The schematics indicate the proteins expressed by the SHIV-89.6 vaccine. CMVIE and IA, the CMV immediate early promoter and intron A; gag and
RT, SIV239 genes for group specific antigen and reverse transcriptase; X, inactivating point mutation in PR; tat, vpu, rev, and env; HIV-1 89.6 auxiliary and envelope
genes; BGHpA, the bovine growth hormone polyadenylation sequence. Levels of expressed GM-CSF are for transiently transfected 293T cells. (B) Immunization and
challenge schedule. Immunizations in trans used DNA/89.6.VLP plus DNA/GM-CSF. Immunizations in cis used DNA/89.6.VLP.GM-CSF. The challenge was an
intra-rectal challenge with SHIV-89.6P (see Materials and methods for details). (C) Similar protection in plus and minus GM-CSF groups. Boxplots provide a graphic
summary for peak viral loads in the trial groups. The white line within the box is the median, the upper and lower limits of the boxes indicate the 75th and 25th
percentiles respectively. Minimum and maximum values are indicated by the upper and lower brackets. Vaccine groups and the number of animals in each group (n) are
indicated below the box plots.
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copies per ml), whereas the mean for the unvaccinated controls
remained high (5.2×104). Shedding of virus in the stool was
monitored for the challenge at 100 weeks, a challenge which
included only adjuvanted animals and unvaccinated controls.
These analyses revealed that the adjuvanted vaccine also had
reduced viral shedding (p=0.008) (Fig. 2B).
The GM-CSF adjuvant also showed increased protection
against CD4 T cell loss, with this achieving significance in the
intestines (p=0.05) but not the blood (Figs. 2C, D and F). At
their lowest point, colorectal CD4 Tcells were reduced to 18% of
CD3 T cells in the adjuvanted group, 13% of CD3 T cells in the
non-adjuvanted group and 3% of CD3 T cells in the un-vaccinated group. These levels represented 42%, 31% and 5% of
the normal levels of colorectal CD4 T cells for the three groups
respectively. By 12 weeks post challenge, CD4 T cells had
recovered to 36%, 24% and 8% of CD3 T cells (86%, 57% and
19% of normal colorectal levels) in the three trial groups,
respectively. In the blood, CD4 T cells were reduced to 36% of
total CD3 cells, or 68% of their normal levels in the two
vaccinated groups whereas reduction was to 8% of CD3 T cells,
or 15% of normal levels in the unvaccinated animals. By
12weeks post challenge, blood had recovered 84% of the normal
level of CD4 T cells in the GM-CSF-adjuvanted group, 66% of
the normal level in the non-adjuvanted vaccine group, and only
24% of the normal level in the unvaccinated controls. The rapid
Fig. 2. Post challenge control of SHIV-89.6P viral RNA and protection of CD4 T cells. (A and B) Temporal titers of viral RNA in the blood and stool are presented as
geometric means±standard deviations. Stool samples are for 8 macaques vaccinated in the presence of GM-CSF and 4 control macaques. Data are not available for the
no GM-CSF group because stool samples were first harvested at the 100 week challenge, a time when only control and plus GM-CSF animals underwent challenge.
(C and D) Temporal frequencies of CD4 T cells as a % of total CD3 cells in blood and colorectal biopsies are presented as averages±standard deviations. Data for
colorectal CD4 T cells are available for only part of the animals in each group at the different time points due to restrictions on the frequency of biopsies and the
changing of harvest times as data were obtained for temporal responses. Symbols for the different groups are given in panel A. Pre, samples taken 2–3 weeks prior to
challenge but plotted at the time of challenge. (E and F) Statistical analyses for protection against peak viremia and preservation of colorectal CD4 T cells. The
statistical analysis for colorectal CD4 T cells was done for 8 weeks post challenge, a time for which more data were available than for week 12. Explanation of the
boxplots is given in Fig. 1.
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vaccinated group likely reflects the ability of SHIV-89.6P to use
both CXCR-4 and CCR-5 co-receptors. Naïve CD4 T cells
bearing CXCR-4 (Zhang et al., 2000) predominate in the blood,
whereas memoryCD4 T cells displaying CCR-5 as well as
CXCR-4 predominate in the intestines (Pitcher et al., 2002).
Serum IgG antibody responses
The GM-CSF adjuvant did not affect the titers of elicited IgG
for the 89.6 or 89.6P Envs in serum (Fig. 3A). Binding Ab was
first detected for the 89.6 Env following the 1st MVA boost; and
for the 89.6P Env, after the 2ndMVA boost. The titers of binding
Ab rose and fell with boosts, with each boost increasing peak
titers. Post challenge, both adjuvanted and non-adjuvanted
vaccine groups exhibited strong anamestic expansions of anti-
Env IgG. This expansion was highest in the non-GM-CSFgroup, a finding consistent with the higher titers of post
challenge virus in this group. Binding Ab also appeared in the
serum of the unvaccinated controls, but at peak viremia had
1000-times lower titers than in the vaccinated animals (Fig. 3A).
Although GM-CSF did not serve as an adjuvant for higher
titers of anti-Env binding Ab, it did serve as an adjuvant for the
avidity maturation of anti-Env Ab. The avidity of the elicited
anti-Env IgG was consistently higher as it rose over time for the
plus GM-CSF than the minus GM-CSF group (p=0.004 to
p=0.009) (Fig. 3B). The higher avidity was seen for both the
89.6 and 89.6P Envs. Post challenge, the range of values ob-
served for the 89.6P Env broadened, a finding that would be
consistent with the challenge boosting the primed Ab responses
as well as eliciting new Ab that had not yet undergone avidity
maturation.
Serum neutralizing Ab for both SHIV-89.6 and SHIV-89.6P
was higher in the non-adjuvanted than the adjuvanted group
Fig. 3. Post challenge Ab responses in the blood. The left column shows data for the 89.6 Env and the right column, for the 89.6P Env. (A) Geometric mean titers for
anti-Env binding IgG determined using ELISAs. Titers of IgG are relative to a standard curve of macaque IgG. Vertical dashed lines indicate the times of D (DNA) and
M (MVA) immunizations and 89.6P (SHIV-89.6P) challenge. Pre, samples taken prior to immunization but plotted at the time of the 1st immunization. Weeks post
challenge are indicated by “+” preceding the week number. (B) Boxplots showing avidity indices for anti-Env binding Ab harvested at different times in the trial. See
legend to Fig. 1 for explanation of graphic. Horizontal lines above or below plots indicate outliers. (C) Geometric mean titers for neutralizing activity for SHIV-89.6
and SHIV-89.6P. Titers are serum dilutions at which relative luminescence units were reduced 50% compared to virus control wells.
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first detected after the 2nd MVA boost and underwent a further
boost following the challenge. The unvaccinated controls
showed much lower titers of post challenge neutralizing Ab
than the vaccinated groups, with neutralizing activity not
appearing in the controls until 12 weeks post challenge.
IgA antibody responses
Unexpectedly, the GM-CSF-adjuvanted, but not the non-
adjuvanted group, had a long-lived anti-SIV IgA response in
rectal secretions (Fig. 4). At the time of challenge, 8 of the 16
GM-CSF-adjuvanted animals, but none of the non-adjuvanted
animals, had anti-SIV IgA in rectal secretions (Fig. 4B). Theanti-SIV IgA was not present in the blood of GM-CSF adju-
vanted animals at the time of challenge, indicating that the
specific IgA in the secretions had originated from the rectal
mucosa rather than from serum transudate or blood contaminant
(Fig. 4A). The anti-SIV IgA was likely against SIV Gag/Pol
because the SIV lysate contained very limited levels of Env. The
anti-SIV IgA response was present in secretions collected at 32
(GM-CSF delivered in trans) and 60 weeks (GM-CSF delivered
in cis) after the last MVA boost indicating that the GM-CSF
adjuvanted vaccine had supported a long lasting IgA response.
Post challenge, the GM-CSF-adjuvanted group continued to
have a good frequency of animals with anti-SIV IgA in rectal
secretions. By 2 weeks post challenge anti-Mn gp120 IgA had
appeared in the rectal secretions of the GM-CSF-adjuvanted
Fig. 4. Temporal anti-viral IgA in rectal secretions and serum. Data are the specific activity of an anti-viral response (ng of anti-viral IgA per μg of total IgA). (A)
Temporal geometric means for anti-SIV Gag/Pol IgA for the different groups. The left hand panel shows data for rectal secretions and the right hand panel, for serum.
Closed square, plus GM-CSF; Open circle, minus GM-CSF; Closed triangle, unvaccinated. (B) Temporal data for individual animals for anti-Gag/Pol (SIV-239) IgA,
anti-gp120 (MN) IgA and anti-gp41 (MN) IgA in rectal secretions. Significant values (mean plus 3 S.D. of 15 naïve macaques) are highlighted and boxed. One outlier
in the unvaccinated controls with constitutive high levels of IgA in rectal secretions is not included in the data set. b, values below the background for detection
(0.005 ng of IgA/μg of total IgA); pre, samples taken 2–3 weeks prior to challenge but plotted at the time of challenge; wk, week; nt, no test; blanks, no sample.
158 L. Lai et al. / Virology 369 (2007) 153–167animals. This response was detected in 8 of the 16 animals in the
adjuvanted group, but none of the 4 in the non-adjuvanted
group. Post challenge, anamestic responses for Anti-SIV IgA
and anti-Mn gp120 IgA also occurred in the bloods of the
vaccinated animals (Fig. 4A and data not shown). Following the
challenge, an anti-gp41 IgA response appeared in all groups,
including one unvaccinated control, suggesting that gp41 is a
particularly good target for anti-viral IgA. When both pre and
post challenge IgA responses for SIV and gp120 were
considered, the difference in the elicitation of IgA between
the adjuvanted and unadjuvanted vaccine groups was highly
significant (p=0.003).The IgA antibodies were measured using the specific activity
of the elicited IgA (ng of SIV-specific IgA/total IgA) to
normalize for differences in the recovery of IgA in rectal
secretions and minimize artifacts that can occur in tests for IgA.
Data on the presence of anti-viral IgA in rectal secretions are not
available for the immunization phase of the trial because these
assays were not undertaken until the time of challenge.
T cell responses
Intracellular cytokine (ICS) and tetramer analyses revealed
overall similar patterns of expansion and contraction for
159L. Lai et al. / Virology 369 (2007) 153–167responding CD4 and CD8 T cells in the blood from the plus and
minus-GM-CSF groups (Figs. 5A and 6A). In contrast to the
sequential increases in titers of anti-Env IgG with the threeMVA
boosts, both CD8 and CD4 T cell responses achieved their
highest values following the 1st MVA boost. Following the 2nd
and 3rd MVA boosts, the CD8 responses underwent some
expansion, whereas the CD4 responses underwent undetectable
to minimal increases. Post challenge, the frequencies of anti-
viral CD8 and CD4 T cells rapidly expanded, achieving fre-
quencies approximating their original peak. By 5 weeks post
challenge these responses were contracting, likely in response to
reduced viral loads. Anti-viral CD8 and CD4 T cells wereFig. 5. Analyses for responding Tcells using ICS assays. (A) Temporal CD8 and CD4
times of immunization and challenge are indicated by vertical dotted lines (see legend
time of the 1st immunization. Weeks indicated with a “+” are weeks post challenge.
challenge for CD8 T cells and CD4 T cells for the different trial groups. Data are exp
group; open bar, minus GM-CSF group; and hatched bar, unvaccinated controls. Supresent at much lower levels in the unvaccinated controls than in
the vaccinated groups following challenge.
Multicolor flow cytometry conducted on responding T cells
at 3 weeks post challenge revealed no differences in cytokine co-
expression patterns between the adjuvanted and non-adjuvanted
vaccine groups (Figs. 5B and C). Both vaccine groups differed
from the unvaccinated group in having much higher proportions
of CD8 T cells co-expressing IFN-γ, IL-2, and TNF-α, or co-
expressing IFN-γ and IL-2. In the unvaccinated group, the
predominant responding cells expressed IFN-γ and TNF-α, only
IFN-γ or only TNF-α (Fig. 5B). Expression patterns for anti-
viral CD4 T cells were also similar in the adjuvanted and non-Tcell measured as IFN-γ producing cells as a % of total CD8 or CD4 Tcells. The
to Fig. 3 for detail). Pre, samples taken prior to immunization but plotted at the
(B and C) Characterization of cytokine co-production profiles at 3 weeks post
ressed as number of expressing cells per ml of blood. Filled bar, plus GM-CSF
fficient CD4 T cells were not present in the unvaccinated controls for analyses.
Fig. 6. Temporal CD8 T cells in blood and rectal biopsies for the
immunodominant Gag-CM9 epitope. Temporal frequency of tetramer staining
cells throughout the trial. Weeks indicated with a “+” are weeks post challenge.
Pre, samples taken prior to immunization but plotted at the time of the 1st
immunization. Analyses for colorectal cells were initiated at the time of
challenge and are not available for the vaccination period of the trial.
160 L. Lai et al. / Virology 369 (2007) 153–167adjuvanted vaccine groups (Fig. 5D). Sufficient anti-viral CD4 T
cells were not available for analyses for post challenge co-
expression profiles in the unvaccinated controls.
Post challenge, the GM-CSF-adjuvanted group had as high
frequencies of tetramer-staining cells in colorectal biopsies as in
the blood (Fig. 6). The responding cells in the intestines showed
the same temporal expansion as those in blood. During the 1st
week post challenge, limited to no expansion of CD8 Tcells was
observed in the blood, or the intestines. However, by 2 weeks
post challenge, rapid expansions had taken place at all 3 of these
sites (Fig. 6). In contrast, in the no-GM-CSF group, the re-
sponding cells in the intestines showed a slower temporal
appearance than in blood, and were present at lower frequencies
(Fig. 6). Statistics were not done on the relative appearance of
responding cells in the intestines in the GM-CSF-adjuvanted and
non-adjuvanted groups because of small sample sizes, which
were smaller than group sizes due to restrictions on the fre-
quency of biopsy collection and the adjustment of sampling
times as information was gained on the tempo of mucosal
responses. Data on the relative presence of tetramer-staining
cells in colorectal samples from adjuvanted and non-adjuvanted
groups are not available for the immunization phase of the trial
because these assays were not instituted until the time of
challenge.
Correlations
Correlations were undertaken to determine the role of GM-
CSF adjuvanted (Figs. 7A, B) as well as non-GM-CSF adju-
vanted immune responses in protection (Fig. 7C). A response
was considered to be GM-CSF adjuvanted if it had shown a
significant difference between the GM-CSF and non-GM-CSF
groups during the immunization phase of the trial. Two antibody
responses met these criteria, the avidity of anti-Env IgG and the
presence of anti-viral IgA in rectal secretions (Figs. 3 and 4).
Correlations for protection utilized data from the vaccinated, but
not unvaccinated groups.
The pre-challenge as well as post challenge avidity of anti-
Env IgG in serum showed consistent correlations with protection(Fig. 7A). These correlations revealed animals with the highest
avidity anti-Env Ab having 1000-times lower titers of virus at
peak virema than those with the lowest avidity anti-Env Ab. Pre-
challenge, r values ranged from −0.6 to −0.7 and p values from
b0.0001 to 0.003. Post challenge, the r and p values for the
challenge Env (89.6P), but not the immunogen Env (89.6)
decreased, consistent with the lowering of the avidity due to the
challenge Env eliciting new Ab as well as expanding the primed
Ab.
Correlations for the presence of anti-viral IgA in rectal
secretions and protection were done using data for anti-SIV IgA
and anti-Mn gp120, because these specificities distinguished the
vaccine and control groups. These correlations were done for the
presence of anti-SIV IgA pre challenge and for the presence of
anti-SIVor anti-gp120 IgA either pre or post challenge. The anti-
viral IgA response, which was scored as present or absent, did
not show a significant correlation with protection. However,
animals with the lowest post challenge peak viral loads were
uniformly IgA positive.
Three other immune responses, which were not affected by
GM-CSF, also showed correlations with protection (Fig. 7C).
The 1st of these, the frequency of IFN-γ producing anti-viral
CD4 T cells, showed a weak correlation with protection (r=
−0.5, p=0.01) at 1 week following the 1st MVA boost. The
other two correlations were observed post challenge. At 2 weeks
post challenge, tetramer staining cells in the blood showed a
strong correlation with protection (r=−0.8, p=0.01) and at
3 weeks post challenge, colorectal tetramer staining cells
showed a strong correlation with protection (r=−0.9, p=0.02).
Discussion
Our studies reveal co-delivery of GM-CSF DNA with the
DNA prime of a DNA/MVA vaccine enhancing protection
against the acute phase of a SHIV-89.6P challenge. Analyses of
immune responses during the vaccine and challenge phases of
the trial revealed Ab, CD4 T cells and CD8 T cells all con-
tributing to protection against the acute infection. The adjuvant
effect of GM-CSF enhanced the protective efficacy of the
elicited Ab, but not of the elicited T cells.
The most important protective effect of GM-CSF on the
elicited Ab was the enhancement of the avidity of anti-Env
binding Ab. Animals with high avidity anti-Env Ab had up to
1000-times lower titers of virus at peak viremia than animals
with low avidity Ab responses. The avidity indices for anti-Env
Ab response underwent a gradual increase throughout the trial
from indices of less than 20 to more than 60. At each time point,
the anti-Env IgG in the GM-CSF adjuvanted group had indices
∼10 points higher than the indices in the non-adjuvanted
animals. Throughout the trial, the avidity indices of the vaccine-
elicited anti-Env IgG showed strong inverse correlations with
peak viral loads (r values as high as −0.8 and p values as low as
b0.0001).
The avidity-mediated protection could reflect a number of
non-neutralizing Ab activities. Ab bound to virus could have
mediated complement (C′) dependent virolysis and opsoniza-
tion (Montefiori, 1997). Ab bound to infected cells could have
Fig. 7. Correlations between adjuvanted and non-adjuvanted vaccine-elicited responses and protection. (A and B) Correlations between GM-CSF-adjuvanted Ab
responses and protection. (C) Correlations between non-adjuvanted T cell responses and protection. All correlations use reductions in peak viremia as a correlate for
protection. The time in the trial for each correlation is given above its graphic. (A) Correlation between avidity of anti-Env IgG with protection. The Env being tested as
a target for anti-Env IgG binding is shown on the right. Note the increasing avidity of the anti-Env IgG response with time in the trial. (B) Test for a correlation between
the presence of anti-viral IgA in rectal secretions and protection. The plus and minus groups were defined based on the presence of anti-SIV IgA or anti-gp120 IgA. See
legend to Fig. 1 for explanation of the graphic. (C) Correlations between T cells responses and protection. The type of T cell being used for the correlation is shown
below its graphic. 20 samples were used in all tests in panel A. For panels B and C the number of samples (n) in each test are indicated below the graphics. Wk, week;
Tet+, tetramer staining.
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complement mediated lysis and Ab dependent cellular cytotoxi-
city (ADCC) (Gomez-Roman et al., 2005). Both virolysis by C′
lysis and killing of infected cells by ADCC contribute to thecontrol of HIV in acutely infected humans (Connick et al., 1996;
Forthal et al., 2007; Huber et al., 2006). The importance of
avidity has long been recognized for neutralizing monoclonals
(Parren and Burton, 2001; Parren et al., 1998). This study
162 L. Lai et al. / Virology 369 (2007) 153–167extends these findings to non-neutralizing mechanisms of Ab-
mediated control of immunodeficiency virus infections.
Surprisingly, the titers of neutralizing Ab did not correlate
with protection. Neutralizing Ab was not present at sufficient
titers pre-challenge to prevent the challenge infection. However,
at the time of challenge, it was present at different titers in
different animals. Why did differences in avidity but not
differences in neutralizing Ab correlate with differences in
peak viral loads? Immunodeficiency viruses are known to
rapidly escape from neutralizing Ab that is present at insufficient
titers to completely block an infection (Parren et al., 1999).
Could avidity have had a greater effect on viral control than
neutralizing Ab by virtue of its being harder to escape than
neutralizing Ab? Such could reflect binding Ab having more
targets on the surface of a virus than neutralizing Ab, which
specifically targets entry functions.
Our detection of avidity playing an important role in Ab-
mediated protection likely reflects a number of our experimental
conditions. Our immunization schedule fostered avidity matura-
tion by providing pulses of antigen at 4-month intervals. We
used native forms of Env for our immunogens and our binding
assays to elicit and test for Ab recognizing the forms of Env on
virions and infected cells. We consider the use of native forms of
Env to have been critical because non-neutralizing mechanisms
of Ab-mediated protection depend on Ab recognizing the forms
of Env that are present on virus and infected cells.
Unexpectedly, the GM-CSF adjuvant also enhanced the
levels of anti-viral IgA in rectal secretions. This enhanced IgA
response showed a trend towards better protection, a trend that
did not achieve significance in our data set. The presence of anti
SIV IgA in rectal secretions at the time of challenge (32 to
60 weeks after the last immunization) suggests that the GM-
CSF-adjuvanted vaccine had established long-lived IgA secret-
ing cells in the rectal mucosa. In general, parenteral immuniza-
tions with inactivated or replication-defective vaccines have
been poor at establishing IgA-secreting plasma cells in the
mucosa (Neutra and Kozlowski, 2006). Thus, the identification
of GM-CSF as an adjuvant for fostering rectal IgA responses
may have considerable use for the development of vaccines that
protect mucosal surfaces.
A single inoculation of GM-CSF DNAwith the single DNA
prime enhanced both the avidity maturation of the anti-Env IgG
response and the presence of mucosal IgA. These findings imply
that the GM-CSF DNA, delivered at the time of the DNA prime,
initiated an immune response that enhanced both the avidity
maturation of Ab and mucosal immune responses. GM-CSF is
well known for its ability to support the expansion and
differentiation of dendritic cells and monocytes (Inaba et al.,
1992). GM-CSF is also known to stimulate the production of IL-
6 (Evans et al., 1998). In mouse studies, the use of GM-CSF as
an adjuvant has consistently enhanced Ab and CD4 T cell
responses (Xiang and Ertl, 1995; Geissler et al., 1997; Kamath et
al., 1999; Lee et al., 1998; Pasquini et al., 1997; Sin et al., 1998;
Weiss et al., 1998; Barouch et al., 2002). In vaccine studies in
primates, it has affected the height of Ab responses(Kumar et al.,
2002; Rogers et al., 2002). In a study in humans, in which Ab
responses were not measured, it appeared to reduce CD8 T cellresponses (Wang et al., 2005).We are the first to have recognized
its potential to foster the avidity maturation of Ab responses (see
also Robinson et al., 2006), and this is the 1st study suggesting
that GM-CSF can foster long-lived colorectal IgA responses.
GM-CSF likely enhanced the avidity maturation of Ab
responses by enhancing germinal center reactions. Interestingly,
IL-6 influences germinal center development (Kopf et al., 1998)
and paracrine IL-6 can promote B cell growth and differentiation
in germinal centers (Burdin et al., 1996). Thus the known ability
of GM-CSF to stimulate IL-6 production could affect its ability
to enhance avidity maturation of anti-Env Ab. As for enhancing
colorectal IgA responses, recent studies in mice show blood
monocytes preferentially giving rise to mucosal dendritic cells
(Varol et al., 2007). In the macaque model, GM-CSF expands
and matures blood monocytes. By analogy to the mouse model,
these monocytes could preferentially become mucosal dendritic
cells (work in progress). Studies in mice also show IL-6
stimulating the presence of IgA-secreting B cells (Mora et al.,
2006). Thus GM-CSF could enhance the presence of mucosal
IgA secreting cells by enhancing the presence of mucosal
dendritic cells as well as by providing IL-6 for the differentiation
of IgA-secreting B cells.
The temporal appearance of binding and neutralizing Ab was
more similar in the plus and minus GM-CSF groups in this study
than in our prior GM-CSF study(Robinson et al., 2006). In the
prior study, both binding and neutralizing Ab appeared in the
GM-CSF-adjuvanted group prior to its appearance in the non-
adjuvanted group. The current study was designed to enhance
Ab responses and used a DNA vaccine that expressed virus like
particles (VLP) and a vaccine regimen that included 3 MVA
boosts. The earlier study used a DNA that expressed a plasma
membrane form of Env and a regimen with only a single MVA
boost. The VLP-expressed Env plus the increased number of
MVA boosts enhanced the elicitation of Ab by about 100-fold,
and likely minimized effects of GM-CSF on the temporal
appearance of anti-Env Ab. However, in both studies, GM-CSF
enhanced the avidity of the anti-Env Ab response. The fact that
enhanced avidity did not enhance neutralizing Ab in this study
likely reflected the elicited avidity in both groups being
sufficient for neutralizing 89.6 and 89.6P. Our hope had been
that the avidities we achieved in this study would extend the
neutralizing activity to incident isolates. This hope was not
realized.
Two non-adjuvanted T cell responses also showed correla-
tions with protection against the acute phase of protection. These
included aweak correlation with themagnitude of the CD4 Tcell
response measured as IFN-γ producing cells at 1 week post the
1st MVA boost and strong correlations between the heights of
tetramer staining CD8 T cells in the blood and intestines early
post challenge. Thus, all arms of the adaptive immune response
contributed to protection: the adjuvanted Ab response and the
non-adjuvanted CD4 and CD8 T cell responses. Of these, only
the adjuvanted Ab response showed a strong pre-challenge cor-
relation with protection.
In conclusion, our studies reveal a remarkable ability of GM-
CSF DNA, when used as an adjuvant for the DNA prime of a
DNA/MVA vaccine, to enhance the avidity maturation of anti-
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secretions. Although the presence of rectal IgA was associated
with the best viral control, this trend did not achieve significance
and will require additional studies to clearly define the role of
anti-viral IgA in protection. The strong correlation of the avidity
of anti-env IgG with protection against peak viremia did achieve
significance. Peak viremia was reduced by 1000-fold in animals
with the highest avidity anti-Env Ab.
Materials and methods
Vaccines
DNA/SHIV.89.6.VLP was constructed from SHIV-89.6
sequences (kindly provided by J. Sodroski) to express SIV239
gag/pol sequences and HIV-1 89.6 env, tat, rev, and vpu
sequences (Fig. 1A). The integrase region of polwas deleted and
an inactivating point mutation was added to the active site in
protease (D25A) to achieve the production of VLPs rather than
the formation of intracellular aggregates by premature cleavage
of over-expressed Gag (Smith et al., 2004). Two DNA/89.6VLP
constructs were made, one with a full length Env and one with a
cytoplasmic tail truncated Env that enhances the exposure of
conserved targets for neutralization in the ectodomain (Edwards
et al., 2002). The truncation was encoded by a frameshift
mutation at amino acid 706 in the cytoplasmic domain (Edwards
et al., 2002). The pGA1 expression cassette was used for
constructs (Fig. 1A) (Genbank AF424297). Rhesus GM-CSF
was expressed either in a dedicated DNA, DNA/GM-CSF
(Robinson et al., 2006); or in the VLP vaccine DNA in the
position of Nef, DNA/89.6.VLP.GM-CSF (Fig. 1A). Expression
of the DNA constructs was tested in transiently transfected 293T
cells using western blots for the expression of Gag and Env and
electron microscopy for the production of VLP (data not shown).
Supernatants were tested for GM-CSF protein using an antigen
capture ELISA for human GM-CSF (BioSource Inc.) (Fig. 1A).
MVA/89.6 was the same as previously described and expressed
SIV239 Gag/Pol in deletion II and a 115 aa C-terminal truncated
SHIV-89.6 Env in deletion III (Amara et al., 2001).
Macaque trials
Vaccinations were conducted in 20 young adult rhesus
macaques, 9 of which contain the A⁎01 histocompatibility type
that presents an immunodominant epitope in Gag (Gag-CM9)
(Allen et al., 1998). Macaques were randomized into 5 trial
groups of four animals each based on weight and A⁎01 status.
Trial groups were then randomized into four inoculation and
sampling groups. A “no GM-CSF” group received a mixture of
1.5 mg of DNA/89.6.VLP and 1.5 mg of pGA1 vector DNA
intradermally (id), two “GM-CSF in trans” groups received a
mixture of either 1.5 mg of DNA/89.6.VLP, or 1.5 mg of DNA/
89.6.VLP with the truncated Env, mixed with 1.5 mg of GM-
CSF DNA id. Two additional “GM-CSF in cis” groups received
3 mg of DNA/89.6/VLP.GM-CSF administered id or intramus-
cularly (im). Intradermal DNA inoculations were delivered as
twelve 0.1 ml shots, 3 to each limb. Intramuscular DNA ino-culations consisted of a single 1 ml inoculation to the thigh.
MVA boosts, 1×108 pfu of MVA/SHIV-89.6, used the same
route as the prime. Intradermal MVA boosts consisted of one
0.1 ml shot of 2.5×107 pfu to each limb; and intramuscular
boosts, of a single 1 ml shot in the thigh. The immunization
schedule consisted of a DNA inoculation at week 0 followed by
three MVA boosts delivered at weeks 8, 24 and 40, (1B).
Intrarectal challenge with an estimated 20 intrarectal infectious
units of SHIV-89.6P (1.1×1010 copies of viral RNA) was
conducted as previously described (Amara et al., 2001). Three
groups, the no-GM-CSF group and the two GM-CSF in trans
groups, were challenged at 72 weeks, and the two GM-CSF in
cis groups at 100 weeks (Fig. 1B). At each challenge, 4 naive
animals served as unvaccinated controls, giving a total of 8
unvaccinated controls. Six of these were A⁎01-positive. The
challenge was staggered to allow for more intensive sampling
and T cell analyses for individual animals. Animals were cared
for under guidelines established by the Animal Welfare Act and
the NIH “Guide for the Care and Use of Laboratory Animals”
using protocols approved by the Emory University Institutional
Animal Care and Use Committee.
Anti-Env IgG
Antigen for detecting anti-Env IgG in serum was produced in
transient transfections of 293T cells with DNA/89.6.VLP.
Lipofectamine-assisted transfections (Invitrogen) were con-
ducted using the supplier's directions and DMEM supplemented
with 10% fetal bovine serum (D-10). At 4 h, cultures were
changed to DMEM without serum. Culture supernatants were
harvested at about 36 h, clarified by low speed centrifugation,
dissociated by adjusting to 1% Triton-X-100 and tested for the
ability to bind anti-Env Ab following capture with concanavilin
A (Con A) (Vector Laboratories) (Cole et al., 1997). ELISA
plates (Costar, Corning Life Sciences) were coated with ConA
by incubating 100 μl of 25 μg per ml Con A in 10 mM Hepes
buffer (pH 7.5) with 0.15 M NaCl, 1 mM CaCl2 and 1 mM
MnCl2 overnight at 4 °C. Plates were washed six times with PBS
containing 0.05% Tween-20 (PBS-tween) following which
100 μl of undiluted VLP supernatant was added, incubated for
one h at room temperature, washed six times with PBS-tween,
blocked for 1 h at room temperature with 100 μl blocking buffer
(PBS-tween with 4% whey and 5% dry milk). Each lot of VLP
supernatant was verified to achieve the same binding as a
standard VLP supernatant using a standard anti-Env serum. The
Triton-treated VLP supernatant was then divided into aliquots
and frozen at−80 °C. For ELISA assays, test sera were diluted in
PBS-tween with 4% whey and 100 μl of serial 3-fold dilutions
added to duplicate wells and incubated for 1 h at room
temperature. The plates were then washed 6 times with PBS-
tween and bound Ab detected using peroxidase conjugated anti-
monkey IgG (Accurate Chemical and Scientific Corp) and TMB
substrate (KPL). Reactions were stopped with 100 μl of 2 N
H2SO4. Each plate included a standard curve generated using
goat anti-monkey IgG and rhesus IgG (both from Accurate
Chemicals) as previously described (Robinson et al., 2006).
Standard curves were fitted and sample concentrations inter-
164 L. Lai et al. / Virology 369 (2007) 153–167polated as μg of Ab per ml of serum using SOFTmax 2.3
software (Molecular Devices). The concentrations of IgG are
relative to our standard curve, not absolute values.
A NaSCN displacement ELISA assay modeled after that
described by Vermont was used for determining avidity
(Vermont et al., 2002). This assay was conducted using parallel
titrations of test sera in our standard ELISA assay. Following the
binding of the test sera, the parallel titrations were treated for
10 min at room temperature with PBS or 1.5 M NaSCN
(prepared fresh in PBS). Then, the relative levels of bound Ab
were determined using the standard ELISA procedure (see
above). The avidity indexwas calculated by dividing the dilution
of the serum that gave an OD of 0.5 with NaSCN treatment by
the dilution of the serum that gave an OD of 0.5 without NaSCN
treatment and multiplying by 100. Each assay included one plate
with a standard serum with known avidity. Between assay
variation for a reference standard included in each assay was ±3
for an index of 27.
Neutralization assay
Neutralization was measured as a function of reductions in
luciferase reporter gene expression after a single round of in-
fection in TZM-bl cells as described (Li et al., 2005; Montefiori,
2004). TZM-bl cells were obtained from the NIH AIDS
Research and Reference Reagent Program, as contributed by
John Kappes and Xiaoyun Wu. Briefly, 200 TCID50 of virus
was incubated with serial 3-fold dilutions of serum sample in
triplicate in a total volume of 150 μl for 1 h at 37 °C in 96-well
flat-bottom culture plates. Freshly trypsinized cells (10,000 cells
in 100 μl of growth medium containing 75 μg/ml DEAE
dextran) were added to each well. One set of control wells
received cells+virus (virus control) and another set received
cells only (background control). After a 48 h incubation, 100 μl
of cells was transferred to 96-well black solid plates (Costar) for
measurements of luminescence using the Britelite Lumines-
cence Reporter Gene Assay System (PerkinElmer Life
Sciences). Assay stocks of SHIV-89.6 and SHIV-89.6P were
prepared in human PBMC (2) and titrated in TZM-bl cells.
Assay stocks of Env-pseudotyped viruses (incident clade B
isolates) were prepared by transfection in 293T cells and were
titrated in TZM-bl cells as described (2).
IgA
Rectal secretions were collected using premoistened Weck-
Cel Sponges (Medtronic ENT) as described (Kozlowski et al.,
2000). Sponges with absorbed secretions were placed in 15 ml
Falcon tissue culture tubes and maintained on ice until storage at
−80 °C. Secretions were extracted from matched sponges by
sequential centrifugation in the presence of 100 μl PBS con-
taining protease inhibitors and 0.5% Igepal detergent (Kozlowski
et al., 2000).
Anti-SIV gag/pol, HIV gp120, and HIV gp41 IgA antibodies
were measured by ELISA as described (Bertley et al., 2004)
using Fisherbrand high protein binding microtiter plates coated
with 250 ng SIVmac251 viral lysate (Advanced BiotechnologiesInc.), 100 ng HIV rgp120MN, and 100 ng HIV rgp41MN (both
ImmunoDiagnostics) in PBS. Positive controls were pooled sera
obtained from SIV-infected or vaccinated macaques (Bertley
et al., 2004). Serum samples collected after challenge were
depleted of IgG before addition to plates as previously described
(Wright et al., 2002). The secondary antibody was affinity-
purified biotinylated goat anti-monkey IgA (Rockland Immu-
nochemicals). Plates were developed with 0.5 μg/ml avidin-
labeled peroxidase and ABTS as described (Bertley et al., 2004).
To account for the variable immunoglobulin concentration in
secretions, the concentration of antigen-specific IgA in each
secretion was divided by the total IgA concentration to obtain its
specific activity. Total IgAwas measured by ELISA (Bertley et
al., 2004) using plates coated with 0.5 μg/ml affinity-purified
goat anti-monkey IgA antibody (Rockland). The standard for
total IgAwas pooled rhesus macaque serum containing a known
amount of IgA (Bertley et al., 2004). Plates were developed as
above. IgA specific activity was considered significant if it was
equal to or greater than the mean+3 S.D. determined from
analysis of the specific antibody in specimens collected from
nonvaccinated normal macaques.Mn Envwas used for the study
because it is a purified Env that has good binding activity for
anti-Env sera and purified 89.6 Env was not available.
T cells
Cells for T cell assays were collected from blood, axillary
lymph nodes and colorectal biopsies. Blood was collected into
CPT sodium citrate tubes (BD Pharmaceuticals) for PBMC
fractionation according to the directions of the provider. Lymph
nodes were minced, ground using a Medimachine (BD
Pharmaceuticals) and then washed in RPMI-1640 plus 10%
fetal bovine serum (R-10). 15 to 20 mucosal biopsies were
obtained from the rectum or distal colon using biopsy forceps
and placed in ice cold RPMI-1640 for transport to the lab. In the
lab, intestinal biopsies were washed twice with ice cold Hank's
buffered saline solution (HBSS) and digested with 350 units per
ml of collagenase IV (Worthington) in HBSS for 2 h at room
temperature on a shaker adjusted to slow speed. The digested
tissue was passed 5-times through a syringe with a 16 gauge
needle, followed by 5-times through an 18 gauge needle,
followed by 5-times through a 23 gauge needle and then filtered
through a 70 μm nylon filter (BD BioScience). Cells were
washed with room temperature R-10. In some experiments,
harvested cells were enriched for lymphocytes by resuspending
in 35% percoll (Sigma), layering over 60% percoll, and
centrifuging at 400×g for 30 min at room temperature to enrich
for lymphocytes. Cells from all sources were stained with
trypan-blue for counting prior to T cell assays. The intestinal
biopsies typically yielded several million cells, 5% to 10% of
which were lymphocytes as evidenced by later staining with
CD3.
All sources of T cells were subjected to tetramer staining and
typing for the presence of CD4 and CD8 T cells. This was done
using a panel of CD3 (Alexa Fluor 700, clone SP34-2, BD
Biosciences PharMingen), CD4 (Percp, clone L200), CD8 (PE-
Texas Red, clone 3B5, Invitrogen,), CD28 (FITC, clone CD28.2,
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clone 3A9, BD Pharmingen) and CXCR4 (PE-Cy7, clone 12G5,
eBiosciences). The levels of CD4 T cells in both the blood and
intestinal biopsies are presented as a % of total CD3 T cells.
Losses of CD4 T cells were calculated using the average % for
each group at a given time divided by the normal %. The normal
levels of CD4 T cells as a % of CD3 T cells were 53±9% for
blood and 42±11% for the intestinal biopsies.
During the immunization phase, PBMC were tested for
intracellular cytokine staining for IFN-γ and IL-2 as previously
described (Amara et al., 2002) but using a single pool of 125
SIV239 Gag peptides (NIH AIDS Research and Reference
Reagent Program) and a single pool of 221 SHIV-89.6 Env
peptides (Emory Microchemical Facility) for stimulations. All
peptides were 15-mers overlapping by 11. Following challenge,
PBMC were tested for intracellular cytokine staining for IFN-γ,
IL-2 and TNF-α using an LSR-II multicolor flow cytometer (BD
Immunocytometry Systems). These stimulations were con-
ducted for Gag and Env using two million PBMC in a total
volume of 200 μl in the presence of anti-CD28 antibody and
anti-CD49d antibody (1 μg/ml; BD Pharmingen). Golgi-stop
(BD Pharmingen) was added after 2 h of incubation. Tubes were
mixed briefly and then incubated for an additional 4 h. Cells
were washed once with cold phosphate-buffered saline (PBS)
containing 2% FBS, surface stained with anti-human CD4
PerCP (clone L200; BD Pharmingen), anti-human CD8 Alexa
Fluor 405 (clone 3B5; Caltag), fixed with cytofix/cytoperm (BD
Pharmingen) and permeabilized with 1× Permwash (BD
Pharmingen). Cells were then incubated for 30 min at 4 °C
with a cocktail of monoclonal antibodies conjugated to different
fluorochromes for the detection of CD3 (FITC, clone FN-18,
BioSource) and cytokines IFN-γ (APC Alexa Fluor 750, clone
B27, Invitrogen), IL-2 (APC, clone MQ1-17H12, BD Pharmin-
gen) and TNF-α (PE-CY7, clone Mab11, eBiosciences). Cells
were washed twice with 1× Permwash, once with 2% FBS in
PBS and resuspended in 1% formalin in PBS. Approximately
500,000 lymphocytes were acquired and analyzed using FlowJo
software (Treestar, Inc.). Lymphocytes were identified based on
their scatter pattern, CD3+, CD8−, CD4+ cells were considered
as CD4 Tcells and CD3+, CD8+, CD4− cells were considered as
CD8 T cells. These CD4 or CD8 T cells were then gated for
respective cytokine positive cells. Boolean gating was per-
formed to calculate the frequencies of the seven different
combinations of cytokines using the FlowJo software. After
subtracting the background, the absolute numbers of the seven
cytokine subsets per ml of blood was determined and plotted for
each antigen per individual.
Viral RNA
Assays for viral RNA were conducted using a quantitative
real time PCR as previously described (Amara et al., 2001;
Hofmann-Lehmann et al., 2000). All specimens were ex-
tracted and assayed in duplicate, with the mean results
reported. Nucleic acid extractions from feces used the RNAqu-
eous-Midi kit (Ambion) according to the directions of the
manufacturer.Statistical analyses
The Wilcoxon rank-sum test was used for pairwise com-
parisons between groups for levels of peak viral RNA, survival
of CD4 Tcells, avidity indices of anti-Env IgG and levels of peak
viral RNA in animals that did, or did not, score for anti-viral IgA
in rectal secretions. To assess the relationship between viral load
and avidity of anti-Env IgG, the Pearson correlation test was
used. The Spearman rank-correlation method was used to
determine correlations between T cell responses and protection.
The Fischer's exact test was used to test for differences in the
presence of anti-viral IgA in plus and minus GM-CSF groups.
For all comparisons between groups, a two-sided pb0.05 was
considered statistically significant. Statistical analyses were
performed using software programs S-PLUS 7.0 and SAS 9.1.
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